< Back to previous page
Researcher
Karen Vanhoorelbeke
- Disciplines:Biochemistry and metabolism, Cardiac and vascular medicine, Medical biochemistry and metabolism
Affiliations
- Chemistry, Kulak Kortrijk Campus (Department)
Responsible
From1 Oct 2018 → Today - Chemistry, Kulak Kortrijk Campus (Department)
Member
From1 Jan 2009 → Today - Faculty of Medicine (Faculty)
Member
From1 Oct 2004 → 30 Sep 2006 - Faculty of Science, Kulak Kortrijk Campus (Faculty)
Member
From1 Oct 2000 → 31 Dec 2008
Projects
1 - 10 of 58
- B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVDFrom1 Oct 2023 → TodayFunding: Horizon Europe - European Innovation Council (EIC)
- A novel targeted therapy to treat bleeding in patients with a left ventricular assist device.From1 May 2023 → TodayFunding: IOF - mandates
- Universal Chimeric Antigen Receptor (UniCAR) T-cell therapy: an innovative treatment for autoimmune diseaseFrom5 Apr 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Universal chimeric antigen receptor (uniCAR)-T cell therapy to treat autoimmune diseases: immune mediated thrombotic thrombocytopenic purpura as a model system.From1 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Flow cytometer for the Interdisciplinary Research Facility Life Sciences at Campus Kulak KortrijkFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Allosteric ADAMTS13 activation: elucidating long-range structural crosstalk bringing the enzyme in a preactivated stateFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- An integrated approach to restore tolerance in autoimmune diseaseFrom1 Oct 2022 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Next-generation DNA vectors to improve efficacy, precision and accessibility of antibody gene transferFrom15 Mar 2022 → 14 Mar 2024Funding: BOF - various
- Innovative approaches to tackle autoimmune diseases: immune-mediated thrombotic thrombocytopenic purpura as a disease modelFrom1 Jul 2021 → 30 Jun 2023Funding: BOF - various
- A novel biomarker to improve the quality of life of immune mediatied thrombotic thrombocytopenic purpura patients.From1 Jun 2021 → 31 May 2023Funding: Foreign foundations, funds with scientific view
Publications
31 - 40 of 210
- Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients(2021)
Authors: Charlotte Dekimpe, Karen Vanhoorelbeke
Pages: 2193 - 2198 - First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination(2021)
Authors: Laure De Waele, Karen Vanhoorelbeke
Pages: 2014 - 2018 - N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP(2021)
Authors: Karen Vanhoorelbeke
Pages: 2694 - 2698 - Novel biosensing concepts for advancing antigen-specific antibody detection(2021)
Authors: Sara Horta, Karen Vanhoorelbeke, Jeroen Lammertyn, Nick Geukens
- Evaluation of Immuno-Rolling Circle Amplification for Multiplex Detection and Profiling of Antigen-Specific Antibody Isotypes(2021)
Authors: Sara Horta, Jolien Breukers, Nick Geukens, Karen Vanhoorelbeke, Jeroen Lammertyn
Pages: 6169 - 6177 - Crystal structure of ADAMTS13 CUB domains reveals their role in global latency(2021)
Authors: Karen Vanhoorelbeke
- The von Willebrand factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice(2021)
Authors: Frederik Denorme, Kim Martinod, Hans Deckmyn, Karen Vanhoorelbeke, Simon De Meyer
Pages: 819 - 828 - Detailed histological analysis of a thrombectomy-resistant ischemic stroke thrombus: a case report(2021)
Authors: Senna Staessens, Raf Sciot, Karen Vanhoorelbeke, Simon De Meyer
- Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura(2021)
Authors: Kadri Kangro, Simon De Meyer, Karen Vanhoorelbeke
Pages: 478 - 488 - Antithrombin p.Thr147Ala: The First Founder Mutation in People of African Origin Responsible for Inherited Antithrombin Deficiency(2021)
Authors: Karen Vanhoorelbeke
Pages: 182 - 191
Patents
1 - 9 of 9
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)